These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24008841)

  • 21. Association of endothelial dysfunction and no-reflow during primary percutaneous coronary intervention for ST-elevation myocardial infarction.
    Levi Y; Sultan A; Alemayehu M; Wall S; Lavi S
    Cardiovasc Revasc Med; 2016 Dec; 17(8):552-555. PubMed ID: 27638105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction.
    Balta S; Celik T; Ozturk C; Kaya MG; Aparci M; Yildirim AO; Demir M; Kilic S; Aydin İ; Iyisoy A
    Am J Emerg Med; 2016 Aug; 34(8):1542-7. PubMed ID: 27238848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.
    Niu X; Zhang J; Bai M; Peng Y; Sun S; Zhang Z
    BMC Cardiovasc Disord; 2018 Jan; 18(1):3. PubMed ID: 29320987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Somuncu MU; Akgun T; Cakır MO; Akgul F; Serbest NG; Karakurt H; Can M; Demir AR
    J Atheroscler Thromb; 2019 Nov; 26(11):970-978. PubMed ID: 30996145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    Wang Z; Ren L; Liu N; Lei L; Ye H; Peng J
    Kardiol Pol; 2016; 74(10):1160-1166. PubMed ID: 27160177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.
    Eitel I; Nowak M; Stehl C; Adams V; Fuernau G; Hildebrand L; Desch S; Schuler G; Thiele H
    Am Heart J; 2010 May; 159(5):882-90. PubMed ID: 20435200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.
    Süleymanoğlu M; Rencüzoğulları İ; Karabağ Y; Çağdaş M; Yesin M; Gümüşdağ A; Çap M; Gök M; Yıldız İ
    Int J Cardiovasc Imaging; 2020 May; 36(5):789-796. PubMed ID: 31919706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combination of plaque components analyzed by integrated backscatter intravascular ultrasound and serum pregnancy-associated plasma protein a levels predict the no-reflow phenomenon during percutaneous coronary intervention.
    Daidoji H; Takahashi H; Otaki Y; Tamura H; Arimoto T; Shishido T; Miyashita T; Miyamoto T; Watanabe T; Kubota I
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):43-50. PubMed ID: 24227626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome.
    Song NP; Zhen XW; Li LD; Zhong L; Wang H; An Y
    BMC Cardiovasc Disord; 2020 Oct; 20(1):443. PubMed ID: 33036574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow.
    Bouleti C; Mathivet T; Serfaty JM; Vignolles N; Berland E; Monnot C; Cluzel P; Steg PG; Montalescot G; Germain S
    Int J Cardiol; 2015; 187():511-6. PubMed ID: 25863293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum Endocan Levels Predict Angiographic No-Reflow Phenomenon in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Intervention.
    Dogdus M; Yenercag M; Ozyasar M; Yilmaz A; Can LH; Kultursay H
    Angiology; 2021 Mar; 72(3):221-227. PubMed ID: 32996338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Buyukkaya E; Poyraz F; Karakas MF; Kurt M; Akcay AB; Akpinar I; Motor S; Turak O; Ozturk OH; Sen N; Akpek M; Kaya MG; Gibson CM
    Am J Cardiol; 2013 Jul; 112(2):187-93. PubMed ID: 23601576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of syntax score and syntax score II to predict "no reflow phenomenon" in patients with ST-segment elevation myocardial infarction.
    Yesin M; Çağdaş M; Kalçık M; Uluganyan M; Efe SÇ; Rencüzoğulları İ; Karabağ Y; Gürsoy MO; Karakoyun S
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1883-1889. PubMed ID: 28664479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum cystatin C levels relate to no-reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction.
    Cheng C; Liu XB; Bi SJ; Lu QH; Zhang J
    PLoS One; 2019; 14(8):e0220654. PubMed ID: 31369621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    Dominguez-Rodriguez A; Abreu-Gonzalez P; Jimenez-Sosa A; Avanzas P; Bosa-Ojeda F; Kaski JC
    Am J Cardiol; 2010 Dec; 106(11):1540-4. PubMed ID: 21094352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment-Elevation Myocardial Infarction Patients: Where Do We Stand?
    Bulluck H; Foin N; Tan JW; Low AF; Sezer M; Hausenloy DJ
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28242607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transient no reflow following primary percutaneous coronary intervention.
    Jinnouchi H; Sakakura K; Wada H; Arao K; Kubo N; Sugawara Y; Funayama H; Momomura S; Ako J
    Heart Vessels; 2014 Jul; 29(4):429-36. PubMed ID: 23807612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Celik T; Balta S; Ozturk C; Kaya MG; Aparci M; Yildirim OA; Demir M; Unlu M; Demirkol S; Kilic S; Iyisoy A
    Angiology; 2016 Aug; 67(7):683-9. PubMed ID: 26369341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: after primary percutaneous coronary intervention.
    Zhao B; Li J; Luo X; Zhou Q; Chen H; Shi H
    Tex Heart Inst J; 2011; 38(5):516-22. PubMed ID: 22163125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Tasar O; Karabay AK; Oduncu V; Kirma C
    Coron Artery Dis; 2019 Jun; 30(4):270-276. PubMed ID: 31026233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.